Geron Corporation Stock News

Geron (GERN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Writing an all-encompassing book on Python machine learning is difficult, given how expansive the field is. But reviewing one is not an easy feat either, especially when it’s a highly acclaimed titl

Geron has been struggling lately, but the selling pressure may be coming to an end soon

Is (GERN) Outperforming Other Medical Stocks This Year?

Geron Corporation has been focused on the development and commercialization of first-in-class telomerase-inhibiting cancer drugs for as long as 30 long years, and it is only now that its solitary prod

Geron Corporation (Nasdaq: GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 150,000 shares of Geron common stock as an inducement to a newly-hired empl

Scholar Rock (NASDAQ: SRRK), a clinical-stage biopharmaceutical company focused on the treatment of serious diseases in which protein growth factors p

The

Shares of Geron Co. (NASDAQ:GERN) have earned an average rating of “Buy” from the eight brokerages that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rate

Geron (NASDAQ:GERN) was downgraded by investment analysts at ValuEngine from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, ValuEngine reports. GERN has be

It can be tough to find public anti-aging companies to invest in.

Geron Corporation (GERN), a late-stage clinical biopharmaceutical company, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) issued a positive opi

BidaskClub upgraded shares of Geron (NASDAQ:GERN) from a sell rating to a hold rating in a report released on Tuesday morning, BidAskClub reports. Other analysts also recently issued research reports

Zymeworks (NYSE:ZYME) and Ocular Therapeutix (NASDAQ:OCUL) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their

Calidi Biotherapeutics Announces Appointment of Jim Schoeneck, Accomplished Biotech Executive, to Board of Directors